Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Kronos Bio Inc (NASDAQ: KRON) closed at $1.05 in the last session, up 1.94% from day before closing price of $1.03. In other words, the price has increased by $1.94 from its previous closing price. On the day, 1.1 million shares were traded. KRON stock price reached its highest trading level at $1.06 during the session, while it also had its lowest trading level at $0.9864.
Ratios:
We take a closer look at KRON’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.24 and its Current Ratio is at 7.24. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Berenberg on September 14, 2022, initiated with a Buy rating and assigned the stock a target price of $12.
On June 24, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $35.H.C. Wainwright initiated its Buy rating on June 24, 2021, with a $35 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 21 ’24 when Frisbee Allison sold 12,105 shares for $1.05 per share. The transaction valued at 12,757 led to the insider holds 204,510 shares of the business.
Lin Charles Y sold 12,036 shares of KRON for $12,685 on Feb 21 ’24. The SR VP, RESEARCH & DEVELOPMENT now owns 234,603 shares after completing the transaction at $1.05 per share. On Feb 21 ’24, another insider, Olek Elizabeth A, who serves as the SR VP, CLINICAL SCIENCE of the company, sold 7,368 shares for $1.05 each. As a result, the insider received 7,765 and left with 193,275 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KRON now has a Market Capitalization of 63099116 and an Enterprise Value of -81625240. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.03 while its Price-to-Book (P/B) ratio in mrq is 0.39. Its current Enterprise Value per Revenue stands at -12.981 whereas that against EBITDA is 0.709.
Stock Price History:
Over the past 52 weeks, KRON has reached a high of $2.29, while it has fallen to a 52-week low of $0.73. The 50-Day Moving Average of the stock is -7.39%, while the 200-Day Moving Average is calculated to be -13.47%.
Shares Statistics:
According to the various share statistics, KRON traded on average about 396.83K shares per day over the past 3-months and 825910 shares per day over the past 10 days. A total of 58.95M shares are outstanding, with a floating share count of 40.07M. Insiders hold about 33.32% of the company’s shares, while institutions hold 31.09% stake in the company. Shares short for KRON as of 1713139200 were 662733 with a Short Ratio of 1.67, compared to 1710460800 on 667838. Therefore, it implies a Short% of Shares Outstanding of 662733 and a Short% of Float of 1.4199998999999999.
Earnings Estimates
The current market rating for Kronos Bio Inc (KRON) reflects the collective analysis of 4.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$0.5, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.27 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.03 and -$2.05 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.72, with 3.0 analysts recommending between -$1.09 and -$2.08.
